Paper Details

  1. Home
  2. Paper Details

Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.

Author: DrozdzDorota, Meyer ReignerSylvie, TirodkarChitra, WaradyBradley A

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the optimal starting dose of subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in pediatric patients with renal anemia. The study found that subcutaneous C.E.R.A. was safe and effective for treating anemia in children, including those not on dialysis. The authors recommend using defined dose-conversion factors to determine the optimal starting dose.
Paper Details　
Original Abstract of the Article :
RATIONALE & OBJECTIVE: The optimum starting dose of intravenous continuous erythropoietin receptor activator (C.E.R.A.) has been previously determined; this study ascertains the optimum starting dose of subcutaneous C.E.R.A. administration in pediatric patients. STUDY DESIGN: Phase 2, open-label, s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.ajkd.2022.11.006

データ提供：米国国立医学図書館（NLM）

Subcutaneous C.E.R.A.: A New Oasis in Pediatric Anemia Treatment

Anemia, a condition characterized by a deficiency in red blood cells, can be a challenging health issue, particularly for children. Pediatric hematologists are constantly seeking ways to improve the lives of children with anemia, and this study investigates the effectiveness of subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) administration in pediatric patients with chronic kidney disease (CKD). The researchers conducted a phase 2, open-label, single-arm, multicenter study to determine the optimal starting dose of subcutaneous C.E.R.A. administration in pediatric patients with anemia related to CKD. The results demonstrated that subcutaneous C.E.R.A. was safe and effective in treating anemia in this patient population, offering a promising new oasis in the desert of pediatric anemia management.

A More Convenient Oasis in the Desert of Anemia

The study found that subcutaneous C.E.R.A. administration effectively increased hemoglobin levels in pediatric patients with anemia secondary to CKD, demonstrating a safe and effective alternative to intravenous administration. This finding offers a more convenient and comfortable treatment option for children, potentially improving their quality of life.

Living Well in the Desert of Anemia

This research offers a glimmer of hope for children living with anemia associated with CKD. The study's findings suggest that subcutaneous C.E.R.A. can be a safe and effective treatment option, potentially leading to improved health outcomes and a better quality of life for these young patients. It's essential to consult with a healthcare professional to discuss the best treatment options for your individual needs.

Dr. Camel's Conclusion

This study sheds light on the potential of subcutaneous C.E.R.A. as a safe and effective treatment for pediatric anemia associated with CKD. This research offers a more convenient oasis in the desert of anemia treatment, potentially improving the lives of children facing this challenging health condition. It's a step forward in providing better care for children with anemia, ensuring they can navigate the desert of their health journey with greater ease and comfort.

Date :
  1. Date Completed 2023-05-23
  2. Date Revised 2023-05-23
Further Info :

Pubmed ID

36587890

DOI: Digital Object Identifier

10.1053/j.ajkd.2022.11.006

Related Literature

Article Analysis
・Effects of darbepoetin alfa injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.